Clarivate Epidemiology’s coverage of hereditary angioedema (HAE) comprises epidemiological estimates of key patient populations in 45 countries. We report the prevalence of HAE for each country,…
Clarivate Epidemiology’s coverage of atrial fibrillation (AF) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of AF for each…
Clarivate’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key hereditary angioedema patient populations covering 171 countries and…
The treatment of newly diagnosed metastatic hormone-sensitive prostate cancer has evolved in recent years with the approval of hormonal agents such as Zytiga (Janssen), Xtandi (Pfizer / Astellas),…
Clarivate Epidemiology’s coverage of PV comprises epidemiological estimates of key patient populations in the major Asia-Pacific pharmaceutical markets (Australia, Hong Kong, Indonesia, Malaysia…
Clarivate Epidemiology’s coverage of PV comprises epidemiological estimates of key patient populations in the major Americas pharmaceutical markets (Argentina, Canada, Chile, Colombia, and Peru…
Clarivate Epidemiology’s coverage of PV comprises epidemiological estimates of key patient populations in the major European pharmaceutical markets (Austria, Belgium, Czech Republic, Denmark,…
Clarivate Epidemiology’s coverage of PV comprises epidemiological estimates of key patient populations in the major emerging pharmaceutical markets (Brazil, China, India, Mexico, Russia, South…
Clarivate’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key Pemphigus vulgaris patient population covering 171 countries and…
Clarivate Epidemiology’s coverage of Pemphigus vulgaris comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence of Pemphigus vulgaris…
Clarivate Epidemiology’s coverage of PV comprises epidemiological estimates of key patient populations in the major Middle East & Africa pharmaceutical markets (Egypt, Nigeria, Saudi Arabia, and…
MARKET OUTLOOKQUESTIONS ANSWERED What patient shares do key therapies and brands garner by the line of therapy in newly diagnosed polycythemia vera patients? What are the quarterly trends in…
Clarivate Epidemiology’s coverage of clostridium difficile infection (CDI) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United…